Canine Leptospirosis: Clinical Signs, Diagnosis, and Zoonotic Implications in Urban Dog Populations

Introduction

Canine leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. The disease is re-emerging in urban dog populations due to increasing rodent reservoirs, environmental contamination, and changes in canine ecology [1, 2]. Urban environments provide ideal conditions for Leptospira transmission: high densities of reservoir hosts (principally rats), stagnant water sources, and insufficient sanitation infrastructure [3]. Dogs serve as both accidental hosts and potential sentinels for human exposure, making the understanding of canine leptospirosis critical for public health [4].

The causative agent, Leptospira interrogans sensu lato, comprises over 250 serovars grouped into serogroups based on lipopolysaccharide (LPS) antigenic structure [5]. In urban settings, the most frequently isolated serovars from dogs include Icterohaemorrhagiae, Canicola, Copenhageni, and Grippotyphosa [6, 7]. Serovar prevalence varies geographically and temporally, influenced by local reservoir host populations and vaccination practices [8].

This review provides an exhaustive examination of the clinical signs, diagnostic modalities, and zoonotic implications of canine leptospirosis in urban dog populations, with emphasis on serovar epidemiology, molecular diagnostics, acute kidney injury (AKI) biomarkers, and One Health surveillance frameworks.

Etiology and Pathogenesis

Bacterial Structure and Virulence Factors

Leptospira are obligate aerobic spirochetes characterized by a double-membrane architecture: an outer membrane containing LPS and lipoproteins, a periplasmic space housing flagella, and an inner cytoplasmic membrane [9]. Pathogenic species possess a 4.6 Mb genome encoding numerous virulence determinants, including adhesins (LigA, LigB, LenA), hemolysins (Sph2, HlyX), and outer membrane proteins (OmpL1, LipL32, LipL41) [10, 11]. LipL32, the major outer membrane lipoprotein, is highly conserved across pathogenic serovars and serves as a primary target for diagnostic assays [12].

Transmission and Host Entry

Transmission occurs through direct contact with infected urine or indirect exposure to contaminated water, soil, or fomites [13]. The spirochete enters the host through mucous membranes (conjunctival, oral, nasal) or abraded skin. Following entry, Leptospira rapidly disseminates via the bloodstream, establishing a leptospiremic phase lasting 4 to 12 days [14]. The bacteria adhere to endothelial cells, penetrate tissue barriers, and colonize the renal tubules, liver, and lungs [15].

Renal Pathophysiology

Renal colonization is the hallmark of chronic infection. Leptospira bind to renal tubular epithelial cells via fibronectin and collagen receptors, inducing a pro-inflammatory cytokine cascade (TNF-alpha, IL-6, IL-1beta) [16]. Tubulointerstitial nephritis develops, characterized by infiltration of mononuclear cells, tubular necrosis, and interstitial fibrosis [17]. The resulting acute kidney injury (AKI) manifests as azotemia, isosthenuria, and proteinuria [18]. The spirochete persists in the proximal convoluted tubules, shedding in urine for weeks to months after clinical resolution [19].

Hepatic and Pulmonary Involvement

Hepatic involvement ranges from mild hepatocellular injury to severe cholestasis. Leptospira LPS triggers Kupffer cell activation and hepatocyte apoptosis, leading to elevated bilirubin and liver enzyme activities [20]. Pulmonary hemorrhage, a life-threatening complication, results from endothelial damage and immune complex deposition in alveolar capillaries [21].

Clinical Signs in Urban Dog Populations

Acute and Subacute Presentations

The clinical spectrum of canine leptospirosis varies from subclinical infection to fulminant multi-organ failure. Urban dogs may present with non-specific signs including fever (39.5 to 41.0 degrees Celsius), lethargy, anorexia, vomiting, and diarrhea [22]. The classic triad of icterus, azotemia, and thrombocytopenia is observed in approximately 40% of cases [23].

Renal and Hepatic Manifestations

AKI is the most consistent clinical finding. Affected dogs exhibit polyuria followed by oliguria or anuria, with serum creatinine and blood urea nitrogen (BUN) concentrations rising rapidly [24]. Hepatic involvement produces icterus of mucous membranes, scleral injection, and bilirubinuria. Serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities are moderately elevated [25].

Coagulopathy and Vascular Leak

Thrombocytopenia (platelet count less than 100,000 per microliter) occurs in 60 to 80% of cases, often accompanied by prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) [26]. Petechiation, ecchymoses, and epistaxis may be observed. Vascular leak syndrome contributes to pulmonary edema and pleural effusion [27].

Subclinical and Chronic Infection

Subclinical infections are common in urban dog populations, particularly in endemic areas. These dogs shed leptospires in urine without overt clinical signs, serving as a reservoir for environmental contamination [28]. Chronic infection is associated with persistent renal carriage and intermittent shedding.

Diagnostic Approaches

Clinical Pathology and Acute Kidney Injury Biomarkers

Routine hematology and serum biochemistry provide supportive evidence but are not diagnostic. The following table summarizes key laboratory findings:

Novel AKI biomarkers have improved early detection. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are upregulated within 24 hours of renal tubular damage, preceding serum creatinine elevation [29, 30]. Serum symmetric dimethylarginine (SDMA) provides a more sensitive indicator of glomerular filtration rate decline than creatinine in dogs with leptospirosis [31].

Serological Diagnosis

The microscopic agglutination test (MAT) remains the reference standard for serological diagnosis. The MAT detects agglutinating antibodies against a panel of live leptospiral serovars [32]. A single titer of 1:800 or greater in a clinically compatible case, or a four-fold rise in paired acute and convalescent sera, confirms infection [33]. Limitations include the need for live antigen panels, cross-reactivity between serogroups, and low sensitivity in early infection [34].

Enzyme-linked immunosorbent assays (ELISAs) targeting LipL32 or whole-cell antigens offer higher throughput and automation. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus provides a methodological parallel for antigen detection platforms, though leptospiral ELISAs typically detect IgM or IgG antibodies [35]. IgM ELISAs are positive as early as day 3 to 5 post-infection, making them useful for acute diagnosis [36].

Molecular Diagnostics

Polymerase chain reaction (PCR) assays targeting the lipL32, secY, or 16S rRNA genes provide high sensitivity and specificity for direct detection of leptospiral DNA [37]. Real-time quantitative PCR (qPCR) enables quantification of bacterial load in blood, urine, and tissue samples [38]. Multiplex PCR panels that differentiate pathogenic from saprophytic species and identify serogroups are increasingly used in reference laboratories [39].

The diagnostic sensitivity of PCR varies by sample type and disease phase. During the leptospiremic phase (first 7 to 10 days), blood PCR sensitivity exceeds 90% [40]. Urine PCR is most sensitive after day 7, when renal colonization is established, with sensitivity ranging from 70 to 95% depending on shedding intensity [41]. A negative PCR does not rule out infection, particularly in antibiotic-treated dogs.

Culture and Dark-Field Microscopy

Culture of Leptospira from blood, urine, or tissue requires specialized media (Ellinghausen-McCullough-Johnson-Harris medium) and incubation for up to 16 weeks [42]. Culture sensitivity is low (10 to 50%) and is primarily used for epidemiological typing rather than clinical diagnosis. Dark-field microscopy of urine has poor sensitivity (less than 10%) and is not recommended for routine diagnosis [43].

Diagnostic Algorithm

The following Mermaid diagram illustrates a recommended diagnostic workflow for suspected canine leptospirosis in urban practice:

flowchart TD
    A[Clinical suspicion: fever, lethargy, vomiting, icterus], > B{Point-of-care tests}
    B, > C[Complete blood count, serum chemistry, urinalysis]
    C, > D{AKI biomarkers: SDMA, NGAL, KIM-1}
    D, > E[Positive AKI biomarkers]
    E, > F{Confirmatory testing}
    F, > G[Blood qPCR for lipL32]
    F, > H[Urine qPCR for lipL32]
    F, > I[MAT paired sera]
    G, > J[Positive PCR: confirm acute infection]
    H, > J
    I, > K[Four-fold titer rise or single titer >= 1:800]
    J, > L[Diagnosis confirmed]
    K, > L
    L, > M[Initiate treatment: doxycycline, supportive care]
    M, > N[One Health notification: public health authorities]

Serovar Prevalence in Urban Dog Populations

Geographic Variation

Serovar distribution in urban dogs reflects local reservoir host ecology. In North American cities, serovars Icterohaemorrhagiae and Canicola predominate, associated with rat and dog reservoirs respectively [44]. In European urban centers, serovars Grippotyphosa and Australis are increasingly reported, linked to rodent and wildlife interfaces [45]. Tropical urban environments show higher prevalence of serovars Copenhageni and Pomona [46].

Temporal Shifts

Vaccination pressure has altered serovar prevalence over time. Widespread use of bivalent vaccines (serovars Canicola and Icterohaemorrhagiae) in the mid-20th century reduced the incidence of these serovars in vaccinated populations [47]. However, serovars not included in vaccines (e.g., Grippotyphosa, Bratislava, Pomona) have emerged as dominant causes of clinical disease in some regions [48].

Risk Factors in Urban Settings

Urban dogs at highest risk include those with access to outdoor environments, particularly parks, green spaces, and areas with known rodent activity [49]. Male intact dogs and dogs aged 2 to 7 years are overrepresented in case series [50]. Seasonal peaks occur during periods of heavy rainfall and flooding, which facilitate environmental survival and transmission of leptospires [51].

Zoonotic Implications and One Health Surveillance

Transmission Risk to Humans

Dogs with leptospirosis shed large numbers of leptospires in urine (up to 10^8 organisms per milliliter), posing a direct zoonotic risk to owners, veterinary staff, and household contacts [52]. Human infection occurs through contact with contaminated urine or environmental surfaces. Urban outbreaks of human leptospirosis have been linked to canine cases in several cities, highlighting the role of dogs as sentinels [53].

One Health Surveillance Framework

Integrated surveillance systems that combine human, animal, and environmental data are essential for early detection and control of leptospirosis outbreaks [54]. Canine serosurveillance provides a cost-effective method for monitoring circulating serovars and identifying high-risk areas. Environmental sampling of water sources for leptospiral DNA using qPCR can identify contamination hotspots [55].

Public Health Interventions

Veterinary diagnostic laboratories should report confirmed canine leptospirosis cases to local public health authorities. Owner education regarding urine handling, environmental disinfection (using bleach or quaternary ammonium compounds), and rodent control is critical [56]. Vaccination of at-risk dogs reduces clinical disease and shedding, thereby decreasing zoonotic transmission potential [57].

Vaccine Coverage and Limitations

Available Vaccines

Commercial bacterin vaccines contain inactivated whole-cell preparations of one to four serovars. The most common formulations include serovars Canicola, Icterohaemorrhagiae, Grippotyphosa, and Pomona [58]. Vaccination induces serovar-specific antibody responses that prevent clinical disease but do not always prevent renal colonization or shedding [59].

Vaccine Coverage Gaps

Current vaccines do not provide cross-protection against all pathogenic serovars. Dogs vaccinated with quadrivalent products remain susceptible to infection with serovars Australis, Bratislava, and Copenhageni [60]. The emergence of non-vaccine serovars in urban populations underscores the need for broader antigen coverage or recombinant vaccines targeting conserved antigens such as LigA or LipL32 [61].

Vaccination Recommendations

The American College of Veterinary Internal Medicine (ACVIM) consensus statement recommends annual vaccination for dogs with outdoor access or living in endemic areas [62]. Initial vaccination requires two doses administered 2 to 4 weeks apart, followed by annual boosters. Vaccination should be delayed in dogs with active leptospirosis due to the risk of immune-mediated adverse reactions [63].

Antimicrobial Treatment and Resistance

First-Line Therapy

Doxycycline (5 mg/kg orally every 12 hours or 10 mg/kg orally every 24 hours for 14 days) is the treatment of choice for canine leptospirosis [64]. Doxycycline eliminates the leptospiremic phase, clears renal carriage, and reduces shedding. For dogs unable to tolerate oral medication, intravenous ampicillin (20 mg/kg every 6 to 8 hours) or penicillin G (25,000 to 40,000 U/kg every 12 hours) is used initially, followed by doxycycline [65].

Antimicrobial Resistance

Acquired antimicrobial resistance in Leptospira is rare but has been reported for streptomycin and sulfonamides [66]. Resistance to doxycycline has not been documented in field isolates, although reduced susceptibility has been observed in vitro under selective pressure [67]. Routine susceptibility testing is not performed due to the fastidious nature of the organism.

Prognosis and Outcome

Mortality and Morbidity

Reported mortality rates in dogs with leptospirosis range from 10 to 30%, with higher rates in cases with pulmonary hemorrhage or severe AKI requiring dialysis [68]. Early diagnosis and aggressive supportive care improve outcomes. Dogs that survive the acute phase typically recover renal function, although persistent proteinuria and hypertension may develop [69].

Long-Term Monitoring

Dogs recovering from leptospirosis should undergo serial serum creatinine, SDMA, and urine protein:creatinine ratio measurements at 1, 3, 6, and 12 months post-infection [70]. Urine PCR testing at 4 to 6 weeks post-treatment confirms clearance of renal carriage. Dogs with persistent shedding should be retreated with doxycycline [71].

Conclusion

Canine leptospirosis remains a significant diagnostic and public health challenge in urban dog populations. The clinical presentation is variable, ranging from subclinical infection to fatal multi-organ failure. Diagnosis requires a combination of clinical pathology, serology, and molecular methods, with qPCR targeting lipL32 providing the highest sensitivity in the acute phase. Serovar prevalence is dynamic, influenced by reservoir host ecology and vaccination pressure. Current vaccines offer incomplete coverage, necessitating continued surveillance and development of broader antigen formulations. The zoonotic potential of canine leptospirosis demands integration of veterinary and public health surveillance under a One Health framework. Clinicians in urban practice must maintain a high index of suspicion, implement appropriate diagnostic algorithms, and educate clients on prevention and zoonotic risk.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[3] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[4] Alton GD, Berke O, Reid-Smith R, et al. Seroprevalence of Leptospira spp. in dogs from southern Ontario. Can Vet J. 2009;50(9):937-942.

[5] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[6] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs. J Am Vet Med Assoc. 2004;225(1):72-77.

[7] Gautam R, Wu CC, Guptill LF, et al. Detection of Leptospira spp. in canine urine by real-time PCR. J Vet Diagn Invest. 2008;20(6):735-741.

[8] Moore GE, Guptill LF, Ward MP, et al. Seroprevalence of leptospiral antibodies in dogs in the United States. J Am Vet Med Assoc. 2006;228(10):1548-1554.

[9] Haake DA, Matsunaga J. Leptospira: a spirochete with a hybrid outer membrane. Mol Microbiol. 2010;77(4):805-814.

[10] Picardeau M, Bulach DM, Bouchier C, et al. Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis. PLoS One. 2008;3(2):e1607.

[11] Murray GL, Srikram A, Henry R, et al. Mutations affecting Leptospira interrogans lipopolysaccharide attenuate virulence. Mol Microbiol. 2010;78(3):701-716.

[12] Haake DA, Chao G, Zuerner RL, et al. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect Immun. 2000;68(4):2276-2285.

[13] Barragan V, Olivas S, Keim P, Pearson T. Critical knowledge gaps in Leptospira transmission. PLoS Negl Trop Dis. 2017;11(11):e0006006.

[14] Faine S. Guidelines for the control of leptospirosis. World Health Organization; 1982.

[15] Athanazio DA, Silva EF, Santos CS, et al. Rattus norvegicus as a model for persistent renal colonization by pathogenic Leptospira interrogans. Acta Trop. 2008;105(2):176-180.

[16] Lowanitchapat A, Payungporn S, Srisawat N, et al. Pro-inflammatory cytokine responses in leptospirosis. Asian Pac J Allergy Immunol. 2020;38(1):1-9.

[17] Yang CW, Wu MS, Pan MJ. Leptospirosis renal disease. Nephrol Dial Transplant. 2001;16(Suppl 5):73-77.

[18] Doudier B, Garcia S, Quennee V, et al. Prognostic factors associated with severe leptospirosis. Clin Microbiol Infect. 2006;12(4):299-304.

[19] Monahan AM, Callanan JJ, Nally JE. Host-pathogen interactions in the kidney during chronic leptospirosis. Vet Pathol. 2009;46(5):792-799.

[20] Marangoni A, Aldini R, Sambri V, et al. Leptospira interrogans lipopolysaccharide induces apoptosis in hepatocytes. FEMS Microbiol Lett. 2004;238(1):29-35.

[21] Croda J, Neto AN, Brasil RA, et al. Leptospirosis pulmonary haemorrhage syndrome is associated with linear deposition of immunoglobulin and complement on the alveolar surface. Clin Infect Dis. 2010;50(5):679-685.

[22] Greene CE, Sykes JE, Moore GE, et al. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:431-447.

[23] Goldstein RE, Lin RC, Langston CE, et al. Influence of infecting serogroup on clinical features of leptospirosis in dogs. J Vet Intern Med. 2006;20(3):489-494.

[24] Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990-1998). J Am Vet Med Assoc. 2000;216(3):371-375.

[25] Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[26] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome of dogs with leptospirosis: 41 cases (2000-2005). J Am Vet Med Assoc. 2007;230(7):1023-1029.

[27] Klopfleisch R, Kohn B, Gruber AD. Pulmonary haemorrhage in dogs with leptospirosis. Vet Pathol. 2010;47(4):694-699.

[28] Harkin KR, Roshto YM, Sullivan JT. Clinical application of a polymerase chain reaction assay for detection of Leptospira spp. in canine urine. J Am Vet Med Assoc. 2003;222(9):1224-1228.

[29] Cobrin AR, Blois SL, Kruth SA, et al. Biomarkers of acute kidney injury in dogs with leptospirosis. J Vet Intern Med. 2013;27(4):790-796.

[30] Legatti SAM, El Dib R, Legatti E, et al. Acute kidney injury in dogs with leptospirosis: a systematic review. J Vet Emerg Crit Care. 2018;28(3):196-205.

[31] Nabity MB, Lees GE, Boggess MM, et al. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for early detection of chronic kidney disease in dogs. J Vet Intern Med. 2015;29(4):1036-1044.

[32] World Organisation for Animal Health (OIE). Leptospirosis. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 2021.

[33] Cole JR, Sulzer CR, Pursell AR. Improved microtechnique for the leptospiral microscopic agglutination test. Appl Microbiol. 1973;25(6):976-980.

[34] Cumberland P, Everard CO, Levett PN. Assessment of the efficacy of an IgM-ELISA and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis. Am J Trop Med Hyg. 1999;61(5):731-734.

[35] Hartleben CP, Leite FP, Monte LG, et al. Serological and molecular characterization of Leptospira spp. in dogs. Pesq Vet Bras. 2013;33(5):629-634.

[36] Bajani MD, Ashford DA, Bragg SL, et al. Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis. J Clin Microbiol. 2003;41(2):803-809.

[37] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan real-time PCR targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[38] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[39] Perez J, Goarant C. Rapid Leptospira identification by direct sequencing of the diagnostic PCR products in New Caledonia. BMC Microbiol. 2010;10:325.

[40] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[41] Rojas P, Monahan AM, Schuller S, et al. Detection and quantification of leptospires in urine of dogs: a maintenance host for the zoonotic disease leptospirosis. Eur J Clin Microbiol Infect Dis. 2010;29(10):1305-1309.

[42] Ellis WA. Leptospirosis. In: Coetzer JAW, Tustin RC, eds. Infectious Diseases of Livestock. 2nd ed. Oxford University Press; 2004:1443-1456.

[43] Vijayachari P, Sugunan AP, Sehgal SC. Evaluation of dark field microscopy as a rapid diagnostic test in leptospirosis. Indian J Med Res. 2001;114:54-58.

[44] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs. J Am Vet Med Assoc. 2004;225(1):72-77.

[45] Mayer-Scholl A, Luge E, Draeger A, et al. Distribution of Leptospira serogroups in dogs from Berlin, Germany. Vector Borne Zoonotic Dis. 2014;14(5):325-331.

[46] Ganoza CA, Matthias MA, Collins-Richards D, et al. Determining risk for severe leptospirosis by molecular analysis of environmental surface waters for pathogenic Leptospira. PLoS Med. 2006;3(8):e308.

[47] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1277-1282.

[48] Harkin KR, Hays MP. Variable clinical and pathologic findings in dogs with leptospirosis. J Vet Intern Med. 2005;19(3):345-350.

[49] Raghavan RK, Brenner KM, Higgins JJ, et al. Evaluations of land cover risk factors for canine leptospirosis: 94 cases (2002-2009). Prev Vet Med. 2011;101(3-4):241-249.

[50] Ward MP. Seasonality of canine leptospirosis in the United States. Vet J. 2002;164